Eisai and Biogen say Alzheimer’s drug successful in slowing cognitive decline

Sep 27 (Reuters) – Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) said on Tuesday that their experimental Alzheimer’s drug had significantly slowed cognitive and functional decline in a large trial of patients with early stages of the disease, marking a rare victory in a field littered with failed drugs. The drug, lecanemab, slowed the … Read more